Association of Upon-Diagnosis Blood Eosinophilic Count with Frequency and Severity of Annual Exacerbation in Chronic Obstructive Pulmonary Disease: A Prospective Longitudinal Analysis

Table 1

Epidemiological and clinical characteristics of the patients diagnosed with COPD.

Variables	Eosinophilic n = 395	Noneosinophilic n = 578	values
Sociodemographic
Age (year)	63.4 ± 5.3	63.9 ± 4.1	0.09
Sex (male)	301 (76.2)	463 (80.1)	0.14
BMI (kg/m^2)	29.2 ± 3.1	29.0 ± 3.7	0.37
Active smoker	313 (79.3)	425 (73.5)	0.04
Pack-year in active smoker	22.3 ± 5.0	17.2 ± 4.8	0.00
Former smoker	20 (5.0)	32 (5.5)	0.73
Comorbidities
Pulmonary hypertension (%)	101 (25.5)	116 (20.0)	0.04
Cor pulmonale	71 (17.9)	82 (14.2)	0.12
Hypertension	255 (64.5)	395 (68.3)	0.22
Coronary artery disease	121 (30.6)	179 (30.9)	0.92
Diabetes melilotus	65 (16.4)	87 (15.0)	0.55
Dyslipidemia	199 (50.4)	254 (44.0)	0.05
Spirometry
FEV1 (%)	73.8 ± 2.4	74.1 ± 2.0	0.21
FEV1/FVC	66.8 ± 2.8	67.0 ± 3.0	0.19
FEV1 improvement after bronchodilator	8.4 ± 1.6	8.7 ± 1.9	0.31
COPD severity score
CAT score (impact level)	13.8 ± 2.3	13.6 ± 2.1	0.16
Low (<10)	54 (13.7)	58 (10.0)	0.07
Medium (10–20)	274 (69.3)	420 (72.7)	0.24
High (21–30)	45 (11.4)	59 (10.2)	0.55
Very high (>30)	22 (5.6)	41 (7.1)	0.35
GOLD categorization	2 (2.3)	2 (2.3)	0.56
I	28 (7.1)	44 (7.6)	0.77
II	355 (89.8)	515 (89.1)	0.72
III	7 (1.7)	9 (1.5)	0.81
IV	5 (1.3)	10 (1.7)	0.61
COPD therapeutics
Short-acting beta agonist	395 (100)	578 (100)	1.00
Long-acting beta agonist	374 (9.5)	562 (9.7)	0.91
Anticholinergics	155 (39.2)	216 (37.4)	0.57
Inhaled corticosteroids	29 (7.3)	47 (8.1)	0.64
Home oxygenation support	35 (8.9)	41 (7.1)	0.30
Rehabilitation	65 (16.4)	100 (17.3)	0.71
Prophylactic vaccination
Pneumococcal vaccination	200 (50.6)	282 (48.8)	0.58
Influenza vaccination	17 (4.3)	26 (4.4)	0.94

COPD = chronic obstructive pulmonary diseases.